Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8WTQ1

UPID:
D104A_HUMAN

ALTERNATIVE NAMES:
Beta-defensin 4; Defensin, beta 104

ALTERNATIVE UPACC:
Q8WTQ1; Q496I2; Q496I3; Q496I4

BACKGROUND:
The protein Beta-defensin 104, with alternative names Beta-defensin 4 and Defensin, beta 104, is recognized for its antimicrobial activity. This protein's ability to work in concert with lysozyme and DEFB103 amplifies its effectiveness in combating microbial invaders, showcasing its vital role in immune defense mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Beta-defensin 104 holds significant promise for identifying new therapeutic avenues. Leveraging its antimicrobial capabilities could lead to innovative approaches in boosting host defense mechanisms against microbial threats.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.